杭州市第一人民医院
Hangzhou First People's Hospital
在本站收录的 61 种疾病中,这家医院列在其中 22 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
杭州市第一人民医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma8 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma67 篇牵头论文
- 胃癌Stomach cancer11 篇牵头论文
- 肺癌Lung cancer51 篇牵头论文
- 胰腺癌Pancreatic cancer23 篇牵头论文牵头 1 项开放试验
- 乳腺癌Breast cancer21 篇牵头论文
- 胶质瘤Glioma8 篇牵头论文
- 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
- 骨肉瘤Osteosarcoma3 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
- 多发性骨髓瘤Multiple myeloma5 篇牵头论文
- 淋巴瘤Lymphoma7 篇牵头论文
- 冠心病Coronary heart disease16 篇牵头论文
- 先天性心脏病Congenital heart disease1 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis2 篇牵头论文
- 法布雷病Fabry disease1 篇牵头论文
- 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
- 白塞病Behçet disease1 篇牵头论文
- IgA 肾病IgA nephropathy0 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis1 篇牵头论文
- Leber 遗传性视神经病变Leber hereditary optic neuropathy0 篇牵头论文
未列出的收录疾病:食管鳞状细胞癌、肝母细胞瘤、脊索瘤、神经母细胞瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、脊柱侧弯、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 8 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文8
- Mechanism of Monocarboxylate Transporter 1 and Its Methylation in Nasopharyngeal Carcinoma Pathogenesis.
- Performance of MRI-based radiomics for prediction of residual disease status in patients with nasopharyngeal carcinoma after radical radiotherapy.
- Synergistic action of Hedyotis diffusa Willd and Andrographis paniculata in Nasopharyngeal Carcinoma: Downregulating AKT1 and upregulating VEGFA to curb tumorigenesis.
- Predictive value of delta radiomics in xerostomia after chemoradiotherapy in patients with stage III-IV nasopharyngeal carcinoma.
- CDC25A inhibition suppresses cell proliferation and induces G1/S‑phase cell cycle arrest in nasopharyngeal carcinoma.
- Parkin enhances sensitivity of paclitaxel to nasopharyngeal carcinoma by activating BNIP3/NIX-mediated mitochondrial autophagy.
- METTL13 promotes nasopharyngeal carcinoma progression through regulating the ZEB1/TPT1 axis.
- A diagnosis model in nasopharyngeal carcinoma based on PET/MRI radiomics and semiquantitative parameters.
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 67 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 7 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。
这些数字背后的记录
牵头的论文67
- Disphosphate based hydrogel microspheres for targeted transarterial radioembolization and chemoembolization therapies.
- Mitochondria-Targeted Icaritin Nanoparticles Induce Immunogenic Cell Death in Hepatocellular Carcinoma.
- Hepatic Arterial Infusion Chemotherapy Enhances the Efficacy of Lenvatinib Plus PD-1 Inhibitors in Hepatocellular Carcinoma Patients with Tumor Thrombosis in the Inferior Vena Cava and/or Right Atrium.
- A Novel tRF, HCETSR, Derived From tRNA-Glu/TTC, Inhibits HCC Malignancy by Regulating the SPBTN1-catenin Complex Axis.
- Deciphering the Role of Necroptosis-Related Long Non-coding RNAs in Hepatocellular Carcinoma: A Necroptosis-Related lncRNA-Based Signature to Predict the Prognosis of Hepatocellular Carcinoma.
- Long non-coding RNA in hepatocellular carcinoma: mechanistic insights and therapeutic perspectives.
- HCC-derived CX3CL1 affects hepatocellular carcinoma prognosis and CX3CR1 + MDSC infiltration.
- METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.
- Impact of Donor CMV-Seropostive Grafts on Prognosis of Liver Transplantation for Hepatocellular Carcinoma.
- Multi-omic analysis reveals elevated BRI3BP expression associated with hepatocellular carcinoma progression and poor prognosis.
- Unraveling the Causal Links Between Immune Traits and Hepatocellular Carcinoma: Insights From a Bi-Directional Mendelian Randomization Study.
- G-LERP/miR-374i-b Attenuates IRI and Suppresses Hepatocellular Carcinoma Progression.
- Microchip Based Isolation and Drug Delivery of Patient-Derived Extracellular Vesicles Against Their Homologous Tumor.
- Is DEB-TACE as locoregional therapy before liver transplantation for hepatocellular carcinoma effective?
- Hepatocellular carcinoma-specific epigenetic checkpoints bidirectionally regulate the antitumor immunity of CD4 + T cells.
- Heterogeneity of hepatocellular carcinoma that responds differently to combination therapy with TACE and Sorafenib as determined by digital spatial gene expression profiling.
- Ferroptosis-inducing nanomedicine and targeted short peptide for synergistic treatment of hepatocellular carcinoma.
- Ferroptosis: a new promising target for hepatocellular carcinoma therapy.
- mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma.
- Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma.
- Preoperative Nomogram Incorporating Clinical Factors, Serological Markers and LI-RADS MRI Features to Predict Early Recurrence of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
- SSNA1 Promotes Hepatocellular Carcinoma Metastasis Via STAT3/EMT Induction.
- Scribble promotes fibrosis-dependent mechanisms of hepatocarcinogenesis by p53/PUMA-mediated glycolysis.
- Protein induced by vitamin K absence or antagonist II: Experience to date and future directions.
- Vertically-Ordered Mesoporous Silica Film Based Electrochemical Aptasensor for Highly Sensitive Detection of Alpha-Fetoprotein in Human Serum.
- BMI1-induced CD127+KLRG1+ memory T cells enhance the efficacy of liver cancer immunotherapy.
- Systemic analysis identifying PVT1/DUSP13 axis for microvascular invasion in hepatocellular carcinoma.
- ATRA sensitized the response of hepatocellular carcinoma to Sorafenib by downregulation of p21-activated kinase 1.
- A mixed blessing for liver transplantation patients - Rapamycin.
- Prognostic implication of early posttransplant hypercholesterolemia in liver transplantation for patients with hepatocellular carcinoma.
- SULT2B1-CS-DOCK2 axis regulates effector T-cell exhaustion in HCC microenvironment.
- Current Status and Prospect of Delivery Vehicle Based on Mesenchymal Stem Cell-Derived Exosomes in Liver Diseases.
- Serum Exosome-Derived piRNAs Could Be Promising Biomarkers for HCC Diagnosis.
- Identification of a brand intratumor microbiome signature for predicting prognosis of hepatocellular carcinoma.
- The predictive value of the modified AFP model for liver transplantation outcomes in multinodular hepatocellular carcinoma patients.
- Fingolimod exerts in vitro anticancer activity against hepatocellular carcinoma cell lines via YAP/TAZ suppression.
- E2F7 promotes mammalian target of rapamycin inhibitor resistance in hepatocellular carcinoma after liver transplantation.
- Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.
- Identification and Verification of a Novel MAGI2-AS3/miRNA-374-5p/FOXO1 Network Associated with HBV-Related HCC.
- Clinical practice guideline on liver transplantation for hepatocellular carcinoma in China (2021 edition).
- RNA binding protein-based risk score model for prognosis prediction of patients with hepatocellular carcinoma.
- Long-term outcomes of deceased donor liver transplantation in hepatocellular carcinoma patients with portal vein tumor thrombus: A multicenter study.
- Reply to 'How to select eligible hepatocellular carcinoma patients with portal vein tumor thrombus for deceased donor liver transplantation?'.
- One Shoot, Two Birds: Alleviating Inflammation Caused by Ischemia/Reperfusion Injury to Reduce the Recurrence of Hepatocellular Carcinoma.
- Methylation site APC112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence.
- Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective study.
- Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study.
- The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?
- DYRK1A reinforces epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma via cooperatively activating STAT3 and SMAD.
- Tumor-suppressive role of microfibrillar associated protein 4 and its clinical significance as prognostic factor and diagnostic biomarker in hepatocellular carcinoma.
- Comment on "Predictors of changes in preoperative tumor stage between dynamic computed tomography and gadoxetate disodium-enhanced magnetic resonance imaging for hepatocellular carcinoma".
- Association of RASSF1A Ala133Ser polymorphism with cancer risk: a updated meta-analysis involving 7362 subjects.
- Multi-omics profiling reveals Chitinase-3-like protein 1 as a key mediator in the crosstalk between sarcopenia and liver cancer.
- CLIC1 Drives Angiogenesis in Hepatocellular Carcinoma by Modulating VEGFA.
- Value of Gd-EOB-DTPA-Enhanced MRI and Diffusion-Weighted Imaging in Detecting Residual Hepatocellular Carcinoma After Drug-Eluting Bead Transarterial Chemoembolization.
- Interleukin-2 inducible T-cell kinase: a potential prognostic biomarker and tumor microenvironment remodeling indicator for hepatocellular carcinoma.
- Effects of terlipressin and somatostatin on liver function after major hepatectomy for hepatocellular carcinoma.
- C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1).
- The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib.
- Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
- Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria.
- Risk factors associated with suicide among hepatocellular carcinoma patients: A surveillance, epidemiology, and end results analysis.
- Key factors and potential drug combinations of nonalcoholic steatohepatitis: Bioinformatic analysis and experimental validation-based study.
- Genome-Wide Profiling of Alternative Splicing Signatures Associated with Prognosis and Immune Microenvironment of Hepatocellular Carcinoma.
- LncRNA MEG8 plays an oncogenic role in hepatocellular carcinoma progression through miR-367-3p/14-3-3ζ/TGFβR1 axis.
- Combination therapy for HCC: from CRISPR screening to the design of clinical therapies.
- Downstaging treatment for patients with hepatocelluar carcinoma before transplantation.
中文论文(未计入)2
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 9 家医院列在胃癌下全国有 211 家医院列在胃癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胃癌开放试验。
这些数字背后的记录
牵头的论文11
- Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer.
- Immunotherapy Combined with Chemotherapy in the First-Line Treatment of Advanced Gastric Cancer: Systematic Review and Bayesian Network Meta-Analysis Based on Specific PD-L1 CPS.
- The mir-371a-373 cluster: A crucial miRNA cluster promotes the malignancy of gastric cancer.
- The relationship between innate/adaptive immunity and gastrointestinal cancer : a multi-omics Mendelian randomization study.
- Comprehensive analysis of the expression, prognostic, and immune infiltration for COL4s in stomach adenocarcinoma.
- Vernodalin Suppresses Tumor Proliferation and Increases Apoptosis of Gastric Cancer Cells Through Attenuation of FAK/PI3K/AKT/mTOR and MAPKs Signaling Pathways.
- The putative role of ferroptosis in gastric cancer: a review.
- Efficiency of complete omentectomy in patients with resectable gastric cancer: a meta‑analysis and systematic review.
- A population-based analysis of malignant gastric tumor in children.
- Double Gastroscopy Resection Is a New Attempt to Treat Gastric Submucosal Tumors: A Case Report.
- Exosomal NNMT from peritoneum lavage fluid promotes peritoneal metastasis in gastric cancer.
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
- Treatment of Advance Gastric Cancer With Disulfiram
- A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Incidence of Pancreatic Fistula After Radical Gastrectomy
- A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
- A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
癌症
肺癌
Lung cancer2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 51 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
杭州有 11 家医院列在肺癌下全国有 251 家医院列在肺癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
- 分期
- 未注明
- 开始
- 2025-04
- 发布
- 登记号
- NCT06862869
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、兰州、北京、南京、南昌、南通、台州、合肥、哈尔滨、大连、太原、广州、成都、无锡、杭州、武汉、江门、济南、深圳、湛江、石家庄、福州、西安、遵义、重庆、银川、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文51
- Rapid and Noninvasive Early Detection of Lung Cancer by Integration of Machine Learning and Salivary Metabolic Fingerprints Using MS LOC Platform: A Large-Scale Multicenter Study.
- Identification and functional characterization of genes associated with lipopolysaccharide in lung adenocarcinoma.
- Blood-brain barrier alterations as an initiator of brain metastasis from lung cancer: a new take on an old story.
- Assessing the carcinogenic potential and molecular mechanisms of arecoline in human lungs: from in silico methods to in vitro validation.
- Toripalimab plus chemotherapy as first-line treatment in extensive-stage small cell lung cancer: a health economic evaluation in China.
- Investigating the role of IDO1 in tumors: correlating IDO1 expression with clinical pathological features and prognosis in lung adenocarcinoma patients.
- Investigating the correlation between IDO1/PD-L1 expression or co-expression and EGFR/KRAS gene mutations in advanced NSCLC.
- Sorafenib-treated Th9 cells exhibit superior anti-tumor effect in lung metastasis.
- TtAgo-coupled-multiplex-digtal-RPA-CRISPR/Cas12a (TCMDC) for EGFR mutations detection.
- The study of transitional care on the psychological state of patients with advanced lung cancer chemotherapy.
- Hepatic metastasis of pulmonary large cell neuroendocrine carcinoma: A case report and literature review.
- Phosphodiesterase 1A physically interacts with YTHDF2 and reinforces the progression of non-small cell lung cancer.
- SEPT9: From pan-cancer to lung squamous cell carcinoma.
- Suppression of PERK/eIF2α/CHOP pathway enhances oridonin-induced apoptosis by inhibiting autophagy in Small-Cell lung cancer cells.
- Comprehensive utilization of in silico approach and in vitro experiment to unveil the molecular mechanisms of mono (2-ethylhexyl) phthalate-induced lung adenocarcinoma.
- Advances in Research on the Anticancer Properties and Mechanisms of Metformin in Lung Cancer.
- Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming.
- ITGB4 is a prognostic biomarker and correlated with lung adenocarcinoma brain metastasis.
- Functional Characterization of Reduced Folate Carrier and Protein-Coupled Folate Transporter for Antifolates Accumulation in Non-Small Cell Lung Cancer Cells.
- A Radiological-Radiomics model for differentiation between minimally invasive adenocarcinoma and invasive adenocarcinoma less than or equal to 3 cm: A two-center retrospective study.
- Long-term survival of stage Ib lung adenocarcinoma with postoperative brain oligometastasis: a case report and literature review.
- Detection of serum SNHG22 and its correlation with prognosis of non-small cell lung cancer.
- Taxus chinensis var. mairei (Lemée et Lévl) Cheng et L.K. Fu overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer via suppression of ERK1/2-related cholesterol biosynthesis.
- Potential of Targeting TDO2 as the Lung Adenocarcinoma Treatment.
- Oleandrin enhances radiotherapy sensitivity in lung cancer by inhibiting the ATM/ATR-mediated DNA damage response.
- SPTBN2 suppresses ferroptosis in NSCLC cells by facilitating SLC7A11 membrane trafficking and localization.
- Scribble promotes fibrosis-dependent mechanisms of hepatocarcinogenesis by p53/PUMA-mediated glycolysis.
- Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation.
- CISD2 promotes lung squamous carcinoma cell migration and invasion via the TGF-β1-induced Smad2/3 signaling pathway.
- MFN2 deficiency affects calcium homeostasis in lung adenocarcinoma cells via downregulation of UCP4.
- The second-generation tyrosine kinase inhibitor afatinib inhibits IL-1β secretion via blocking assembly of NLRP3 inflammasome independent of epidermal growth factor receptor signaling in macrophage.
- A novel risk signature for predicting brain metastasis in patients with lung adenocarcinoma.
- Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.
- Characterization and mechanisms of radioresistant lung squamous cell carcinoma cell lines.
- Lung cancer patient with Tropheryma whipplei and Nocardia co-infection.
- Lung cancer metastasis-related protein 1 promotes the transferring from advanced metastatic prostate cancer to castration-resistant prostate cancer by activating the glucocorticoid receptor α signal pathway.
- SERPINE2/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer.
- Hope and Worry: An Interpretative Phenomenological Analysis of Psychological Experiences Associated With Targeted Drug Therapy Among Patients With Advanced Non-Small-Cell Lung Cancer.
- TNFα antagonist in combination with PD-1 blocker to prevent or retard malignant transformation of B[a]P-induced chronic lung inflammation.
- Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.
- Pulsatilla saponin E suppresses viability, migration, invasion and promotes apoptosis of NSCLC cells through negatively regulating Akt/FASN pathway via inhibition of flotillin-2 in lipid raft.
- Blood exosome PD-L1 is associated with PD-L1 expression measured by immunohistochemistry, and lymph node metastasis in lung cancer.
- Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT.
- GTSE1 Facilitates the Malignant Phenotype of Lung Cancer Cells via Activating AKT/mTOR Signaling.
- Effect of continuous nursing based on the Omaha System on cancer-related fatigue in patients with lung cancer undergoing chemotherapy: a randomized controlled trial.
- LASP1 Induces Epithelial-Mesenchymal Transition in Lung Cancer through the TGF-β1/Smad/Snail Pathway.
- Specific Gut Microbiome and Serum Metabolome Changes in Lung Cancer Patients.
- Downregulation of breast cancer resistance protein by long-term fractionated radiotherapy sensitizes lung adenocarcinoma to SN-38.
- Serum exosomal microRNAs as predictive markers for EGFR mutations in non-small-cell lung cancer.
- Sulforaphane overcomes T790M-mediated gefitinib resistance in vitro through epithelial-mesenchymal transition.
- hsa_circ_0058357 acts as a ceRNA to promote non‑small cell lung cancer progression via the hsa‑miR‑24‑3p/AVL9 axis.
中文论文(未计入)4
- [Intestinal Flora Dysregulation and Lung Cancer: Mechanism Analysis and Clinical Application].
- [Establishment of Human Lung Adenocarcinoma Radioresistant Cell Lines and the Mechanism of Radioresistance].
- [Research Progress in CircRNA and Radiotherapy Resistance of Non-small Cell Lung Cancer].
- [Analysis of gut microbiome in patients with lung adenocarcinoma and lung squamous cell carcinoma].
它在 ClinicalTrials.gov 上的全部试验(任何状态)22
- Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
- A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
- Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer
- A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)
- Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)
- M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
- A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
- Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study
- A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients
- A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
- A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
- Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC
- A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC)
- Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy
- A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy
- A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer
- A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
- EGFR Mutations on ctDNA in Patients With Advanced NSCLC
- ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
- T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
- Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer
- Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer
癌症
胰腺癌
Pancreatic cancer2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 23 篇,占 0.4%。
杭州有 9 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 即将招募Canagliflozin With Gemcitabine in Pancreatic Carcinoma
- 分期
- 不分期
- 开始
- 2023-10
- 发布
- 登记号
- NCT05903703
年龄 18 岁 至 未注明(登记的条件)
牵头:杭州市第一人民医院杭州
- 正在招募Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
- 分期
- II期
- 开始
- 2025-05
- 发布
- 登记号
- NCT07006077
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心杭州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文23
- Complex interplay between type 2 diabetes mellitus and pancreatic cancer: insights from observational and mendelian randomization analyses.
- Demystifying metabolic‒immune crosstalk: how amino acid metabolic reprogramming shapes the malignant phenotype and macrophage polarization of biliary and pancreatic tumors.
- Targeting RhoA expression with formononetin and salvianolic acid B to mitigate pancreatic cancer-associated endothelial cells changes.
- Daurisoline inhibits pancreatic cancer progression by direct binding to PPARα and blocking its ubiquitination-mediated degradation.
- Diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration-based cytology for distinguishing malignant and benign pancreatic cystic lesions: A systematic review and meta-analysis.
- The role of vascular resection and reconstruction in pancreaticoduodenectomy.
- The characteristic "alveolus nest sign" in solid pseudopapillary neoplasm of the pancreas.
- Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and trigger endoplasmic reticulum stress.
- A pancreaticogastric fistula related to intraductal papillary mucinous neoplasm of the pancreas developed during follow-up: A case report and literature review.
- Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8+T cell function and its impact against pancreatic ductal adenocarcinoma.
- Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis.
- KNTC1 as a putative tumor oncogene in pancreatic cancer.
- m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway.
- PDZ-binding kinase aggravates pancreatic neuroendocrine neoplasm progression by activating the AKT/mTOR pathway.
- The net parenchymal thickness predicts pancreatic fistula after pancreaticoduodenectomy: a retrospective cohort study of objective data.
- CDC25C is a prognostic biomarker and correlated with mitochondrial homeostasis in pancreatic adenocarcinoma.
- Selective radical resection for unresectable pancreatic cancer.
- CD44V3, an Alternatively Spliced Form of CD44, Promotes Pancreatic Cancer Progression.
- Inhibition of TRIM32 by ibr-7 treatment sensitizes pancreatic cancer cells to gemcitabine via mTOR/p70S6K pathway.
- Immunological role and prognostic value of SPARCL1 in pan-cancer analysis.
- The MYEOV-MYC association promotes oncogenic miR-17/93-5p expression in pancreatic ductal adenocarcinoma.
- Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report.
- EIF3B promotes cancer progression in pancreatic cancer.
癌症
乳腺癌
Breast cancer2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 21 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
杭州有 9 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery
- 分期
- 不分期
- 开始
- 2023-07
- 发布
- 登记号
- NCT07920094
年龄 18 岁 至 70 岁;仅女性(登记的条件)
牵头:浙江大学医学院附属邵逸夫医院;另有 10 家列出的医院为研究中心台州、宁波、杭州、温州、金华
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文21
- Effects of Continuous Perioperative Esketamine Infusion on Postoperative Depression in Breast Cancer Patients: A Randomized Controlled Double-Blind Trial.
- Predicting Pathological Characteristics of HER2-Positive Breast Cancer from Ultrasound Images: a Deep Ensemble Approach.
- Pan-cancer analysis reveals BAF complexes as immune-related biomarkers and validation in triple-negative breast cancer.
- AI in breast imaging: A systematic review of reader studies evaluating design, performance, and clinical impact.
- Using artificial intelligence system for assisting the classification of breast ultrasound glandular tissue components in dense breast tissue.
- Patient-Reported Outcomes and Complication Profiles of Implant-Based Breast Reconstruction in Patients With Postmastectomy Radiation Therapy.
- Nomogram based on multimodal ultrasound features for evaluating breast nonmass lesions: a single center study.
- Detection and diagnosis of automated breast ultrasound in patients with BI-RADS category 4 microcalcifications: a retrospective study.
- The mechanism and therapeutic potential of lncRNA MIR497HG/miR-16-5p axis in breast cancer.
- Encapsulated Papillary Carcinoma of the Breast: A Review of Clinicopathologic Characteristics, Molecular Mechanisms, and Patient Management.
- ER-positive and BRCA2-mutated breast cancer: a literature review.
- Novel immunotherapies for breast cancer: Focus on 2023 findings.
- Functions and mechanisms of RNA m6A regulators in breast cancer (Review).
- Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US.
- Value of multimodal imaging in the diagnosis of breast sclerosing adenosis associated with malignant lesions.
- Accelerated Perioperative Rehabilitation for Breast Cancer Patients Undergoing Radical Mastectomy: A Systematic Review.
- Nodular fasciitis of the breast: the report of three cases.
- β-elemene induced apoptosis and senescence of triple-negative breast cancer cells through IGF1/IGF1R pathway.
- Value of quantitative sound touch elastography of tissues around breast lesions in the evaluation of malignancy.
- Astragaloside IV inhibits cell proliferation and metastasis of breast cancer via promoting the long noncoding RNA TRHDE-AS1.
- All-Trans Retinoic Acid and Doxorubicin Delivery by Folic Acid Modified Polymeric Micelles for the Modulation of Pin1-Mediated DOX-Induced Breast Cancer Stemness and Metastasis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery
- Fertility Decision and Outcomes in Young Women With Breast Cancer
- A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
- Exploring a Breast Cancer Early Screening Model Based on cfDNA
- To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
- Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two-stage IBBR Augmented With TiLoop® Bra(COSTA)
- Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer
- A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
癌症
胶质瘤
Glioma2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 9 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下
截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胶质瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文8
- HTR1D regulates the PI3K/Akt signaling pathway to impact glioblastoma development and resistance to temozolomide.
- SERPINB6 Promotes Epithelial-Mesenchymal Transition via PI3K/AKT/mTOR Signalling Pathway in Glioma.
- Dual targeting agent Thiotert inhibits the progression of glioblastoma by inducing ER stress-dependent autophagy.
- Tenacissoside H repressed the progression of glioblastoma by inhibiting the PI3K/Akt/mTOR signaling pathway.
- CREB-induced LINC00473 promotes chemoresistance to TMZ in glioblastoma by regulating O6-methylguanine-DNA-methyltransferase expression via CEBPα binding.
- GAS5 attenuates the malignant progression of glioma stem-like cells by promoting E-cadherin.
- N-Glycosylation on Asn50 of SND1 Is Required for Glioma U87 Cell Proliferation and Metastasis.
- LINC01116 promotes the proliferation and invasion of glioma by regulating the microRNA‑744‑5p‑MDM2‑p53 axis.
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 5 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 20 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
牵头的论文3
早期论文(2016–2020 年)5
- Radiosensitizing effects of c‑myc gene knockdown‑induced G2/M phase arrest by intrinsic stimuli via the mitochondrial signaling pathway.
- GSH Activated Biotin-tagged Near-Infrared Probe for Efficient Cancer Imaging.
- Effect of CXCR4 on Apoptosis in Osteosarcoma Cells via the PI3K/Akt/NF-κβ Signaling Pathway.
- AMD3100 combined with triptolide inhibit proliferation, invasion and metastasis and induce apoptosis of human U2OS osteosarcoma cells.
- Triptolide inhibits the growth of osteosarcoma by regulating microRNA-181a via targeting PTEN gene in vivo and vitro.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 12 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
杭州有 9 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- 分期
- I期
- 开始
- 2026-05
- 发布
- 登记号
- NCT07477587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- Reduced ALDH1A1 expression in multiple myeloma cells increases resistance to daratumumab via downregulation of retinoic acid.
- Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review.
- Andrographolide induced ferroptosis in multiple myeloma cells by regulating the P38/Nrf2/HO-1 pathway.
- Defects and countermeasures in laboratory diagnosis of rare IgE multiple myeloma.
- Tumor immune cell infiltration score based model predicts prognosis in multiple myeloma.
血液疾病
淋巴瘤
Lymphoma2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
杭州有 8 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下
这家医院参与的开放试验 5
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
- 分期
- II期
- 开始
- 2025-03
- 发布
- 登记号
- NCT07022223
年龄 18 岁 至 未注明(登记的条件)
牵头:浙江大学医学院附属第二医院;另有 2 家列出的医院为研究中心杭州
- 正在招募ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- 分期
- II/III期
- 开始
- 2024-05
- 发布
- 登记号
- NCT06378138
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、合肥、大连、天津、太原、宜昌、广州、成都、杭州、武汉、沈阳、洛阳、济南、淮安、石家庄、福州、蚌埠、西安、遵义、郑州、重庆、长春、长沙
- 正在招募Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
- 分期
- III期
- 开始
- 2024-08
- 发布
- 登记号
- NCT06520163
年龄 18 岁 至 75 岁(登记的条件)
牵头:宁波大学附属人民医院;另有 3 家列出的医院为研究中心宁波、杭州、温州
- 正在招募Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- 分期
- III期
- 开始
- 2024-05
- 发布
- 登记号
- NCT06521255
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、乌鲁木齐、北京、南昌、天津、广州、成都、杭州、武汉、济南、温州、苏州、郑州、重庆、长春、长沙
- 正在招募A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
- 分期
- I期
- 开始
- 2023-10
- 发布
- 登记号
- NCT05892718
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心杭州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文7
- Bi-targeting of thioredoxin 1 and telomerase by thiotert promotes cell death of myelodysplastic syndromes and lymphoma.
- Multiplexed imaging mass cytometry elicits p-S6 as a therapeutic and prognostic factor in diffuse large B-cell lymphoma.
- Overcoming missed diagnoses of primary central nervous system Lymphoma-The key role of cerebrospinal fluid cytology: a case report.
- SNCA is a potential therapeutic target for COVID-19 infection in diffuse large B-cell lymphoma patients.
- DLD is a potential therapeutic target for COVID-19 infection in diffuse large B-cell lymphoma patients.
- Successful Treatment of Atopic Dermatitis with Dupilumab in a Patient with Non-Hodgkin's Lymphoma.
- Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report.
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
- Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
- ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
- Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
- HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
其他疾病
冠心病
Coronary heart disease2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 16 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
杭州有 11 家医院列在冠心病下全国有 231 家医院列在冠心病下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
- 分期
- IV期
- 开始
- 2025-11
- 发布
- 登记号
- NCT07110415
年龄 40 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、兰州、北京、南京、南宁、哈尔滨、大庆、大连、天津、宁波、广州、张家口、成都、杭州、汕头、沈阳、济南、深圳、湖州、烟台、珠海、石家庄、西安、贵阳、重庆、银川、长春、青岛
- 即将招募OPTIMized Diagnosis and Treatment System Based on AI and Multimodal Imaging Fusion for PCI (OPTIMAI-PCI)
- 分期
- 不分期
- 开始
- 2026-09
- 发布
- 登记号
- NCT07855614
年龄 18 岁 至 80 岁(登记的条件)
牵头:浙江医院;另有 6 家列出的医院为研究中心杭州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文16
- Association between coronary heart disease and cardiometabolic index: a study from NHANES 1999-2018.
- Genetic mapping of serum metabolome to chronic diseases among Han Chinese.
- Comparison of Coronary Angiographic-Derived and Intracoronary Imaging-Based Fractional Flow Reserve in Assessing Coronary Artery Stenosis Severity: A Systematic Review and Network Meta-Analysis.
- Investigating the Correlation between Serum Amyloid A and Infarct-Related Artery Patency Prior to Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients.
- Quantitative Flow Ratio-Derived Index of Microcirculatory Resistance as a Novel Tool to Identify Microcirculatory Function in Patients with Ischemia and No Obstructive Coronary Artery Disease.
- Predictive value of coronary artery computed tomography-derived fractional flow reserve for cardiovascular events in patients with coronary artery disease.
- Association between personality traits and psychological distress among postmenopausal women with coronary heart disease: A cross-sectional survey and mediation analysis.
- The Importance of Integrated Regulation Mechanism of Coronary Microvascular Function for Maintaining the Stability of Coronary Microcirculation: An Easily Overlooked Perspective.
- Alterations in gut microbiota and host transcriptome of patients with coronary artery disease.
- Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease.
- The correlation between lipoprotein(a) elevations and the risk of recurrent cardiovascular events in CAD patients with different LDL-C levels.
- A comment and suggestion on angiography-derived FFR: NiFFR.
- An attempt to better show some results such as the comparison of mortality and major adverse cardiovascular events between the abnormal and normal coronary flow reserve cohorts.
- Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta-analysis of Randomized Controlled Trials.
- RNA modifications in cardiovascular diseases, the potential therapeutic targets.
- Integration of summary data from GWAS and eQTL studies identified novel risk genes for coronary artery disease.
中文论文(未计入)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
- OPTIMized Diagnosis and Treatment System Based on AI and Multimodal Imaging Fusion for PCI (OPTIMAI-PCI)
- Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
- FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery Disease
- Wedge NC - Scoring Balloon Dilatation Catheter
- Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease
- Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease
- Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease
其他疾病
先天性心脏病
Congenital heart disease2021–2025 年中国大陆作者发表的 2,604 篇先天性心脏病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.04%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 9 家医院列在先天性心脏病下全国有 207 家医院列在先天性心脏病下
截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的先天性心脏病开放试验。
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
杭州有 10 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- 分期
- III期
- 开始
- 2026-09
- 发布
- 登记号
- NCT07687459
年龄 40 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、运城、郑州、长春、长沙
- 正在招募A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- 分期
- II期
- 开始
- 2025-11
- 发布
- 登记号
- NCT07121413
年龄 40 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、南京、南昌、呼和浩特、天津、广州、徐州、成都、杭州、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
杭州有 10 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募The Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease
- 分期
- 不分期
- 开始
- 2025-03
- 发布
- 登记号
- NCT06765499
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心杭州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
法布雷病
Fabry disease2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 7 家医院列在法布雷病下全国有 80 家医院列在法布雷病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。
其他疾病
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 7 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 7 家医院列在白塞病下全国有 139 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 10 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 7 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
其他疾病
Leber 遗传性视神经病变
Leber hereditary optic neuropathy2021–2025 年没有牵头Leber 遗传性视神经病变的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 5 家医院列在Leber 遗传性视神经病变下全国有 30 家医院列在Leber 遗传性视神经病变下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。
这些数字背后的记录
联系这家医院
出示给工作人员或司机的院名卡
杭州市第一人民医院
Hangzhou First People's Hospital
杭州
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR
Affiliated Hangzhou First People's Hospital; Changzhou First People's Hospital; Affiliated Hangzhou First Hospital; Affiliated Hangzhou First People Hospital; Changzhou & Changzhou First People's Hospital; Hangzhou first people's Hospital; Hangzhou First People Hospital; Changzhou First Hospital